News Release

August 30, 2024
JCR Pharmaceuticals Co., Ltd.

Translation

JCR Continues Support for Relay For Life Japan and Relay For Life of ASHIYA

August 30, 2024-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; headquarters: Ashiya, Hyogo, Chairman and President: Shin Ashida; "JCR") is pleased to announce its ongoing sponsorship of Relay For Life Japan and Relay For Life of ASHIYA, hosted by the Japan Cancer Society.
Relay For Life is a global charity initiative aimed at supporting cancer patients and their families, fostering a community-wide effort to combat cancer.

This year, a dedicated team of our employees will participate in the Relay Walk and Candlelight Run taking place in Ashiya, Hyogo, from September 7 to 8.
At JCR, we are committed to making a difference, especially in addressing the needs of those affected by ultra-rare diseases, ensuing that no one is left behind.

About Relay For Life

Relay For Life began in 1985 when a single doctor ran on a track for 24 hours, raising funds for the American Cancer Society. This event, symbolizing the constant battle cancer patients face, has since grown into a global movement held in 34 countries at approximately 2,460 locations.
In Japan, Relay For Life has also gained momentum, with around 50 events scheduled nationwide in 2024. The Ashiya event, officially launched in 2007, will mark its 18th year under the theme, "Here, I began my walk. Here, I will meet you again."

Please refer to the official websites below for more information about these activities.

- Relay For Life Japan (only in Japanese): https://relayforlife.jp/
- Relay For Life of ASHIYA (only in Japanese): https://relayforlife.jp/ashiya/

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in

development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

Contact:
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com

###